Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab vs fumaric acid esters in moderate to severe plaque psoriasis (phase 4)
2016-003867-21Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in plaque psoriasis comparing Brodalumab (Kyntheum) arm with Fumaric acid esters (Fumaderm) arm (2 arms). Primary endpoint: PASI75 at Week 24. Started Aug 2017; status: completed.
02
Drugs
brodalumabFumaderm
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-003867-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003867-21.